Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells-Reference-Cited by-同舟云学术

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Published:2018-04-19 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Oberg Hans H.,Kellner Christian,Gonnermann Daniel,Sebens Susanne,Bauerschlag Dirk,Gramatzki Martin,Kabelitz Dieter,Peipp Matthias,Wesch Daniela

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference75 articles.

1. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes;Rimawi;Cancer,2010

2. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development;Singh;Br J Cancer,2014

3. HER2-positive breast cancer;Loibl;Lancet,2017

4. Anti-HER2 cancer therapy and cardiotoxicity;Babar;Curr Pharm Des,2014

5. Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention;Nocera;Front Pharmacol,2016

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The therapeutic role of γδT cells in TNBC;Frontiers in Immunology;2024-06-12

2. Identifying a Novel Eight-NK Cell-related Gene Signature for Ovarian Cancer Prognosis Prediction;Current Medicinal Chemistry;2024-04

3. The application of antibody-based agents in cancer therapy based on their mechanisms of action;Fundamental Research;2024-04

4. Integrative single-cell analysis: dissecting CD8 + memory cell roles in LUAD and COVID-19 via eQTLs and Mendelian Randomization;Hereditas;2024-01-31

5. Resistance to Immunotherapy in Breast Cancer;Overcoming Breast Cancer Therapy Resistance;2024